Advertisement
Advertisement
U.S. markets close in 1 hour 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4519-0.0081 (-0.55%)
As of 02:52PM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • s
    sharon
    All is not lost here, especially if the market believes the company's present late-stage candidates can garner support from trial data coming to market over the next several months.....the reality here is; clvs shares could easily pop if funding ensures operations can be sustained for more time to come....funding = partnership/buyout.....first things first funding via a parntership!! worst case; we drift back to that 56c or the 52 week low which would be a huge buying opportunity for that partnership or buyout......if we did not have a promising pipeline which has targetted readout's coming in the back half of 2022 then i would not be here......i do have to admit i should have sold over 3 when i was in profits but i did not relent on the buyout thesis......i can afford to wait this out as i am well diversified which has sustained my trades with profits!!
  • e
    explorador
    “Turning to Rubraca, following the positive results from ATHENAMONO, we believe Rubraca represents an important new option as a front-line maintenance treatment of ovarian
    cancer, and we are on track for submissions to the FDA and EMA during the third quarter of 2022. Lastly, we look
    forward to the anticipated Phase 3 data readout of TRITON3 in the second-line prostate cancer treatment setting
    for selected patients now expected early in the fourth quarter this year and ATHENA-COMBO in combination with
    Opdivo in the front-line ovarian cancer maintenance treatment setting in the rst quarter of 2023.
  • F
    Frank
    This company should have some positive PR statement every week. Silence is a slow drift downward spiral. He did not get his RS and dilution because he is not doing his job. His primary objective as CEO is share price. He could not invent a drug if he tried. He should do what he is paid to do. Right now.... that is to sell the company.
  • n
    n3designs
    CEO Patrick Mahaffy has been more than transparent about his openness to a buyout, saying during 2019’s J.P. Morgan confab that “Everybody knows where to find me and every company in this industry is for sale.”
    Bullish
  • C
    Carl
    Worst of the worse, how many years.?
  • s
    sharon
    Pat is the problem not the FDA ~~ BP can get thru an extension study as well as clovis' debt......years of mis-management is why the stock price is where it is at and why Pat continues to mismanage the company as he stalls for a higher buyout price (my opinion).....buyout or bankruptcy is where we are at and shareholders should be angry......
  • l
    longvrts
    8/16 Rucaparib competition related news: Lynparza in combo with abiraterone gets Priority Review sNDA in met CR prostate cancer indication. FDA did not require OS data. CLVS is getting squeezed on all sides- time to sell the company, which I heard the BOD is more actively involved with:

    "Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
    PUBLISHED
    16 August 2022
    16 August 2022 07:00 BST

    First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations

    AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

    Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.

    The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the fourth quarter of 2022.

    In the US, prostate cancer is the second most common cancer in male patients and is projected to cause approximately 35,000 deaths in 2022.2 Overall survival for patients with mCRPC is approximately three years in clinical trial settings, and even shorter in the real world.3-6 Approximately half of patients with mCRPC may receive only one line of active treatment, with diminishing benefit of subsequent therapies.6-11

    Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “There remains a critical unmet need among patients diagnosed with metastatic castration-resistant prostate cancer, where the prognosis remains poor and treatment options are limited. Today’s news is another step towards bringing forward a new, much-needed treatment option in this setting. If approved, Lynparza with abiraterone will become the first combination of a PARP inhibitor and a new hormonal agent for patients with this disease.”

    Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer, MSD Research Laboratories, said: “MSD is committed to developing new treatment options for patients with metastatic castration-resistant prostate cancer, a complex disease that urgently needs more therapies. We look forward to working with the FDA towards the goal of bringing a new option to patients with mCRPC with or without HRR gene mutations.”

    The sNDA was based on results from the PROpel Phase III trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and later published in NEJM Evidence.

    These results showed Lynparza in combination with abiraterone reduced the risk of disease progression or death by 34% versus abiraterone alone (based on a hazard ratio [HR] of 0.66; 95% confidence interval [CI] 0.54-0.81; p<0.0001). Median radiographic progression-free survival (rPFS) was 24.8 months for Lynparza plus abiraterone versus 16.6 for abiraterone alone. The safety and tolerability of Lynparza in combination with abiraterone was in line with that observed in prior clinical trials and the known profiles of the individual medicines.12

    Lynparza is approved in the US for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations) who have progressed following prior treatment with enzalutamide or abiraterone; and in the EU, Japan and China for patients with BRCA-mutated mCRPC who have progressed following prior therapy that included a new hormonal agent (NHA). These approvals were based on the data from the PROfound Phase III trial.

    Notes

    Metastatic castration-resistant prostate cancer
    Metastatic prostate cancer is associated with a significant mortality rate.13 Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone.14

    In patients with mCRPC, their prostate cancer grows and spreads to other parts of the body despite the use of androgen-deprivation therapy to block the action of male sex hormones.7 Approximately 10-20% of men with advanced prostate cancer will develop castration-resistant prostate cancer (CRPC) within five years, and at least 84% of these men will have metastases at the time of CRPC diagnosis.7 Of patients with no metastases at CRPC diagnosis, 33% are likely to develop metastases within two years.6

    Despite the advances in mCRPC treatment in the past decade with taxane and new hormonal agent (NHA) treatment, there is high unmet need in this population.7,9,10,15
  • b
    bobo
    Someone tell me why this company has a bod that has watched millions evaporate and have done nothing except collect there pay where is accountability American greed at it best my thoughts
  • L
    Larry
    Pat if you’re listening , give me a minute to explain here. I, like many others have been with the company in and out for a few years now. We’ve believed in the company and it’s mission, always hoping for the best. Most of us have looked for the good, even though we were seeing management with your lead, make decisions we felt were contrary to where we thought the company should be going. Maybe at one time you had good intentions, maybe you lost sight of the mission the company should have stayed on, maybe you were just plain ole overwhelmed, I don’t know. What I do know is I’m not going to use this opportunity to beat up on you , that’s not the right thing to do, nor is it my style. Pat, it’s time to think of all your shareholders who have stayed with you, some putting theirselves in financial discomfort hoping you would bring this company on home to above our expectations.
    Pat, negotiate a good deal now, get the most out of a deal that you can, knowing you may have gotten a little sidetracked for a while , but you’re going to do the right thing for all still involved. That’s the right way to walk away Pat, doing what’s best for the shareholders and preserving what you can of the pipeline to put the company in the right hands who can take this company to the next level and beyond and help save peoples lives. Thanks for your time Pat.
    Bullish
  • M
    MIKE C
    From Oncology Times: In a discussion about high grade serous carcinoma of the ovary, Anniina Farkkila, MD, PhD of the University of Helsinki notes that "tumors with BRCA1/2 mutation are more sensitive to immunotherapies that target T cells, such as immune checkpoint blockade. This would also mean that these tumors would likely benefit from combination therapies with, for example, PARP inhibitors and immunotherapies"
  • l
    lillie
    The countries where the most adults have committed… adultery. You might be thinking of France, but the Country of Love came in fifth place. The winner was actually Thailand, with 56% (that's right, most of) the adults having cheated on a spouse at least once. Denmark and Germany came in second and third, with 46% and 45%, respectively.
    Bearish
  • l
    longvrts
    8/12 FAP-2286 news: cancer imaging trial NCT04621435 expanded to include 64Cu in addition to 68Ga to image initial tumor and metastases. Trial is being run at UCSF by Tom Hope, world's leading radioligand imaging expert, as Principal Investigator:

    https://clinicaltrials.gov/ct2/history/NCT04621435?A=1&B=6&C=merged#StudyPageTop
    History of Changes for Study: NCT04621435
    clinicaltrials.gov
  • D
    Dane
    Three string weeks ahead of us and we close august above 3, what do you think?
    Bullish
  • Z
    Z
    This level of disregard for shareholders will never be achieved again. Votes say we want a buyout and partnership, this guy continues to look for other options. Mappy never heard of Transparency as a CEO lol
  • F
    Frank
    This company can not go to the equity markets,preferred or common, at $1.50/ share. The dilution effect would lose money for any investor... and they would have to sell 200,000,000 new shares to keep the circus going for a few months longer. A BO is the only answer.
  • M
    MIKE C
    So here's the scoop: In high grade serous carcinoma of the ovary (HGSC) with HRD, there is more antigenic abnormality than in ovarian cancer with wt HR. Patients with HGSC with HRD respond to parp inhibitor treatment. Patients who have tumors that have high mutational burden respond to treatment with checkpoint inhibitor Patients with HGSC with HRD treated with a parp inhibitor have sustained responses. Patients with HGSC with HRD treated with both a parp inhibitor and a checkpoint inhibitor would therefore be expected to have very deep sustained responses to this combination therapy. Without doubt, BMY knows this, and Pat knows this, The market does not yet appreciate this little factoid. It will soon.
    Less
  • F
    Frank
    So does this thing eventually Implode or Explode. Whatever, please do it soon. This screenplay is cliche and and the actors need to retire. The plot is too much Hollywood and not enough Morningwood.
  • j
    john
    Mahaffey should resign the proxy vote amounted to a no confidence vote in his leadership. A B/O is the only pathway right now or a co-marketing agreement with BP.
  • H
    Harry
    When u buy securities, Mgmt is very important…
Advertisement
Advertisement